Results 231 to 240 of about 85,599,608 (253)
Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10210-10217, November 2026.ABSTRACT Aims Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are commonly withheld during hospitalisation because of concerns about diabetic ketoacidosis. We examined whether hospitalisation was associated with discontinuation of SGLT2i and compared patterns with another anti‐hyperglycaemic medicine without similar inpatient safety concerns ...
Tamara Y. Milder +13 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10236-10247, November 2026.ABSTRACT Aims To identify low‐ and high‐risk intervals for major adverse cardiovascular events (MACE) and all‐cause mortality according to lipid ratios in adults with Type 2 diabetes mellitus (T2DM), stratified by sex. Materials and Methods We used primary care electronic health records from the Spanish National Health Service including 303 199 adults ...
Enrique Carretero‐Anibarro +5 more
wiley +1 more source
Comparison of medication persistence and adherence in type 2 diabetes using a once-weekly regimen of DPP-4 inhibitor compared with once-daily and twice-daily regimens: a retrospective cohort study of Japanese health insurance claims data. [PDF]
Diabetol IntMiwa T +4 more
europepmc +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10664-10669, November 2026.ABSTRACT Background and Aims People with diabetes and chronic kidney disease (CKD) may be at increased risk of iatrogenic hypoglycaemia. We compared rates of sensor‐detected (SDH) and person‐reported hypoglycaemia (PRH) in people with insulin‐treated Type 2 diabetes (T2D) with and without CKD in the Hypo‐METRICS study.
Julie M. B. Brøsen +39 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10765-10779, November 2026.ABSTRACT Aims To examine the association between initiation of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors and risk of incident depression compared with dipeptidyl peptidase‐4 (DPP‐4) inhibitors among adults with newly diagnosed Type 2 diabetes receiving metformin.
Sangwoo Park +5 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10780-10794, November 2026.ABSTRACT Objective Treatment response in type 2 diabetes (T2D) varies widely among individuals. This study aimed to quantify the contributions of clinical characteristics and genetic predisposition as measured through partitioned polygenic risk scores (pPRS) to variation in glycemic response to glucose‐lowering therapies.
S. Garg +4 more
wiley +1 more source
Summary of Research: Efficacy and Safety of the SGLT2 Inhibitor Empagliflozin Versus Placebo and the DPP-4 Inhibitor Linagliptin Versus Placebo in Young People with Type 2 Diabetes (DINAMO): A Multicentre, Randomised, Double-Blind, Parallel Group, Phase 3 Trial. [PDF]
Diabetes TherLaffel LM.
europepmc +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10498-10512, November 2026.ABSTRACT Aims Cardiorenal evidence for glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) derives mainly from trials in overweight or obesity; data in adults with Type 2 diabetes (T2D) and body mass index (BMI) below 27 kg/m2 are limited. Materials and Methods We emulated a target trial in the TriNetX US Collaborative Network (index dates 2020 to ...
Shao‐Chia Chen +6 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10725-10735, November 2026.ABSTRACT Aims To conduct indirect treatment comparisons (ITCs) of insulin efsitora alfa (efsitora) versus insulin icodec (icodec) in insulin‐experienced individuals with Type 2 Diabetes Mellitus. Methods Efficacy, safety and patient reported outcomes were compared via matching‐adjusted ITCs using results from randomised controlled trials: QWINT‐3 ...
Harpreet S. Bajaj +8 more
wiley +1 more source